Comparison  of  efficacy, safety, and costs between neoadjuvant hypofractionated radiotherapy and conventionally fractionated radiotherapy for esophageal carcinoma

Abstract

Background We compared the efficacy, safety, and costs of hypofractionated radiotherapy (HFRT) and conventional fractionated radiotherapy (CFRT) for the neoadjuvant treatment of esophageal cancer. Materials and Methods Overall, 110 patients with esophageal cancer treated with neoadjuvant chemoradiotherapy from October 2002 to July 2017 were retrospectively included and divided into a HFRT group (42 patients received 30 Gray [Gy]/10 fractions for 2 weeks) and a CFRT group [68 patients received 40 Gy/20 fractions for 4 weeks]. Concurrent chemotherapy comprised cisplatin combined with either 5‐FU or taxane. Surgery was performed 3‐8 weeks after radiotherapy. We compared the outcomes, adverse events, and costs between the two groups. Results Pathological downstaging was achieved in 78.6% of the HFRT group and 83.8% of the CFRT group ( P = 0.612). Compared with the CFRT group, the HFRT group had similar pathological complete response (pCR) (33.3% vs 35.3%; P = 0.834), median overall survival (OS) (40.8 months vs 44.9 months; P = 0.772) and progression free survival (32.7 months vs 35.4 months; P = 0.785). The perioperative complication rates were also similar between the groups, but the treatment time and costs were significantly reduced in the HFRT group ( P < 0.05). Finally, multivariate analysis identified cN0 stage, pathological downstaging and pCR as independent predictors of better OS. Conclusion Preoperative HFRT is effective and safe for esophageal cancer. Moreover, it is similar to CFRT in terms of overall survival and toxicity and is cost effective and less time consuming.

Outcomes and Tolerability of Definitive and Preoperative Chemoradiation in Elderly Patients With Esophageal Cancer: A Retrospective Institutional Review

“…With advances in the planning and delivery of conformal radiation, there has also been growing interest in hypofractionation (>2 Gy per daily fraction with lower cumulative dose). 31 This approach may be beneficial for elderly patients given reduced treatment duration with potentially improved tolerability.…”

Impact of radiotherapy on the immune landscape in oesophageal adenocarcinoma

“…With respect to the use of hypofractionation in the curative setting for oesophageal cancer, there is an increasing volume of evidence demonstrating the safety and efficacy of this approach[ 27 ]. There are studies demonstrating a survival benefit of this approach particularly in the context of metastatic nodal disease.…”

Benefits of Adopting Hypofractionated Radiotherapy as a Standard of Care in Low-and Middle-Income Countries

“…54 Another study from China reported that neoadjuvant 10-fraction hypofractionated radiation for esophageal cancer resulted in a 41% reduction in radiotherapy costs over a 20-fraction moderately hypofractionated regimen. 53 Reducing the treatment costs patients incur is equally important to reducing the costs for the overall health care system. The cost associated with traveling, finding housing, and missing work can carry staggering consequences for patients.…”